Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMN-71
- Development stage
- Preclinical
- Lead developer
- Omnix Medical
- Modality
- Peptides
- Administration
- Topical
01
Overview
OMN-71 is an antimicrobial peptide (AMP) currently in preclinical development by Omnix Medical for the treatment of skin and topical infections. The drug is a genetically engineered version of natural peptides from the Cecropin family, designed to physically disrupt and destroy bacterial cell membranes. This mechanism of action is intended to provide broad-spectrum activity against pathogens associated with conditions like acne and atopic dermatitis, including antibiotic-resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA), while minimizing the potential for the development of bacterial resistance. OMN-71 is formulated for topical administration.
Beyond the preview
Go deeper on OMN-71.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMN-71.